|
- Clinical applications and utility of ctDNA in cervical cancer and its . . .
Most studies focus on cervical samples to do research work about cervical cancer and precancerous lesions, but no sensitive or specific biomarkers were found High-throughput genomic technologies are able to capture information from tumors and precancerous lesions in blood, thus providing a new way for the early diagnosis of cervical precancer
- Emerging biomarkers and molecular targets for precision medicine in . . .
In conclusion, the evolving landscape of biomarkers and molecular targets presents exciting opportunities for advancing precision medicine in cervical cancer By harnessing these insights, clinicians can optimize treatment selection, enhance patient outcomes, and ultimately transform the management of this devastating disease
- Exploration of biomarkers for the diagnosis, treatment and prognosis of . . .
As the fourth most diagnosed cancer, cervical cancer (CC) is one of the major causes of cancer-related mortality affecting females globally, particularly when diagnosed at advanced stage Discoveries of CC biomarkers pave the road to precision medicine for better patient outcomes High throughput omics technologies, characterized by big data production further accelerate the process To date
- Biomarkers in the Screening and Management of Cervical Cancer
Every biomarker has been evaluated for its significance in clinical settings beginning from screening, risk categorization to treatment response, and monitoring of tumor relapse
- AI-Driven Advances in Women’s Health Diagnostics: Current Applications . . .
Results: We highlight ten promising AI applications across imaging, laboratory diagnostics, patient monitoring digital biomarkers, and decision support, including AI-enhanced fetal ultrasound, cervical screening, preeclampsia prediction with cell-free RNA, noninvasive endometriosis testing, remote maternal–fetal monitoring, and reinforcement
- Unveiling diagnostic and therapeutic strategies for cervical cancer . . .
Abstract Cervical cancer (CC) is a major global health problem and leading cause of cancer deaths among women worldwide Early detection through screening programs has reduced mortality; however, screening compliance remains low Identifying non-invasive biomarkers through proteomics for diagnosis and monitoring response to treatment could improve patient outcomes Here we review recent
- Full article: Molecular markers for cervical cancer screening
This makes the use of a so-called triage test indispensable for population-based screening to avoid referring women, that are ultimately at low risk of developing cervical cancer, to a gynecologist This review will give an overview of tests that are based on epigenetic marker panels and protein markers
- Unveiling diagnostic and therapeutic strategies for cervical cancer . . .
Cervical cancer (CC) is a major global health problem and leading cause of cancer deaths among women worldwide Early detection through screening programs has reduced mortality; however, screening compliance remains low Identifying non-invasive biomarkers through proteomics for diagnosis and
|
|
|